Contraindications
ChemicalBook > CAS DataBase List > Fondaparinux sodium

Fondaparinux sodium

Contraindications
Product Name
Fondaparinux sodium
CAS No.
114870-03-0
Chemical Name
Fondaparinux sodium
Synonyms
Fondaparin SodiuM;Arixtra;Fondaparinux and intermediates;decasodium 6-[[6-[[2-carboxylato-4-hydroxy-6-[[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)-3-oxanyl]oxy]-5-sulfonatooxy-3-oxanyl]oxy]-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatoox;Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-α-D-glucopyra;a-D-Glucopyranoside, methylO-2-deoxy-6-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(14)-O-b-D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(14)-O-2-O-sulfo-a-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-,6-(hydrog;decasodiuM (2R,3S,4S,5R,6R)-3-{[(2R,3R,4R,5R,6R)-5-{[(2R,3R,4R,5S,6S)-6-carboxylato-5-{[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoaMino)-6-[(sulfonatooxy)Methyl]oxan-2-yl]oxy}-3,4-dihydroxyoxan-2-yl]oxy}-3-(sulfonatoaMino)-4-(sulfonatooxy)-6-[(sulfonatoo;(2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-Carboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-;D01844;Arixtra (tn)
CBNumber
CB41456602
Molecular Formula
C31H43N3O49S8.10Na
Formula Weight
1728.08
MOL File
114870-03-0.mol
More
Less

Fondaparinux sodium Property

Melting point:
>209°C (dec.)
alpha 
D23 +48° (c = 0.61 in water)
storage temp. 
2-8°C
solubility 
Water
form 
Solid
color 
White to Off-White
InChIKey
XEKSTYNIJLDDAZ-UWCYYFDCNA-D
More
Less

Safety

HS Code 
3822000002
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H332Harmful if inhaled

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P271Use only outdoors or in a well-ventilated area.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P312Call a POISON CENTER or doctor/physician if you feel unwell.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
1282718
Product name
Fondaparinux sodium identification
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
30MG
Price
$760
Updated
2024/03/01
Sigma-Aldrich
Product number
1282707
Product name
Fondaparinux sodium for Assay
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
0.6ML
Price
$601
Updated
2024/03/01
Cayman Chemical
Product number
24033
Product name
Fondaparinux (sodium salt)
Purity
≥95%
Packaging
1mg
Price
$33
Updated
2024/03/01
Cayman Chemical
Product number
24033
Product name
Fondaparinux (sodium salt)
Purity
≥95%
Packaging
5mg
Price
$106
Updated
2024/03/01
Cayman Chemical
Product number
24033
Product name
Fondaparinux (sodium salt)
Purity
≥95%
Packaging
10mg
Price
$190
Updated
2024/03/01
More
Less

Fondaparinux sodium Chemical Properties,Usage,Production

Contraindications

Fondaparinux sodium injection is contraindicated in the following conditions:
Severe renal impairment (creatinine clearance <30 mL/min) in prophylaxis or treatment of venous thromboembolism.
Active major bleeding.
Bacterial endocarditis.
Thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.
Body weight <50 kg (venous thromboembolism prophylaxis only).
History of serious hypersensitivity reaction (e.g., angioedema, anaphylactoid/anaphylactic reactions) to fondaparinux sodium.

Description

Fondaparinux sodium was first introduced in the US for prophylaxis of deep vein thrombosis which may lead to pulmonary embolism following major orthopaedic surgery. Fondaparinux is the first of a new class of antithrombic agents distinct from low molecular weight heparin (LMWH) and heparin. This entirely synthetic molecule is a copy of the heparin pentasaccharide sequence, the shortest fragment able to catalyze antithrombin lllmediated inhibition of factor Xa thereby inhibiting thrombin generation without antithrombin action. Fondaparinux does not display significant effects on coagulation tests (such as activated partial thromboplastin time and prothrombin time), does not bind to platelet factor 4 or promote heparin-induced thrombocytopenia. In phase III studies, fondaparinux significantly reduced the incidence of thromboembolism following orthopedic surgery, with an overall risk reduction of 50% in comparison to the LMWH, enoxaparin. Following subcutaneous administration, fondaparinux has a nearly complete bioavailability, a rapid onset of action, a prolonged half-life (17.2 h) enabling once daily dosing and is not metabolized preceeding renal excretion. The drug appears to be generally safe, with haemoragic complications either comparable to or higher than those for LMWH.

Chemical Properties

White Powder (after lyophilisation)

Originator

Sanofi-Synthelabo (France)

Uses

Fondaparinux sodium has been used to test its neutralizing effect towards enterovirus D68-947 infection. It may be used in ultraviolet photodissociation (UVPD) measurements.

Uses

Synthetic pentasaccharide corresponding to the anti-thrombin binding site of heparin. Anti-thrombotic.

Definition

ChEBI: An organic sodium salt, being the decasodium salt of fondaparinux.

Indications

Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for:
Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery.
Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin.

brand name

Arixtra (GlaxoSmithKline).

Biochem/physiol Actions

Fondaparinux sodium is an antithrombotic anticoagulant, a Factor Xa inhibitor. Fondaparinux sodium is chemically related to low molecular weight heparins. Its pentasaccharide structure corresponds to the antithrombin III (ATIII) binding site of heparin. Fondaparinux sodium binding at this site potentiates the natural inhibitory effect of ATIII against factor Xa by a factor of approximately 300, which results in inhibition of thrombin generation.

Clinical Use

Prophylaxis of deep vein thrombosis
Treatment of deep vein thrombosis, pulmonary embolism, unstable angina and after a myocardial infarction

Side effects

Fondaparinux sodium is a prescription medication and as such, most people do not have serious side effects. However, pain, bruising, redness, and swelling at the injection site may occur, as well as headache, nausea, vomiting, swelling of the hands and feet, or fever. A few serious side effects may occur: easy bleeding or bruising; dark urine, yellowing of the eyes or skin; shortness of breath, coughing up blood, chest pain, unusual dizziness, fainting, fast or irregular heartbeat; joint or muscle pain; confusion. Very few patients may experience allergic reactions (e.g. rash, itching or swelling (especially on face/tongue/throat); severe dizziness, difficulty breathing).

Synthesis

Starting from Dglucose, D-cellobiose, and D-glucosamine, the production process for the synthesis of the pentasaccharide involves about 55 steps. The synthesis was accomplished by preparing a fully-protected pentasaccharide, and then converting it into the final product. The choice of protecting groups was dictated by two factors: the need to introduce sulfate substituents (O- as well as N-linked), carboxylate groups and hydroxyl groups, in the proper positions on the target molecule, and the constraints of current methods for oligosaccharide synthesis, particularly the use of 2-azido glucose derivatives to achieve stereoselective introduction of |á-D-linked glucosamine units. All the monosaccharide synthons were obtained from glucose or from glucosamine, and the synthesis is outlined in the scheme. Trisaccharide 108 and disaccharide 109 are the two key building blocks in the synthesis. Coupling 108 and 109 was carried out at -20??C in DCE. Fully protected pentasaccharide 110 was then converted into the target compound 10 using traditional methods: saponification, O-sulfation, cleavage of benzyl ethers with simultaneous reduction of azido into amino functions and finally N-sulfation. Preparation of trisaccharide building block 108 started from 1,6-anhydrocellobiose (111). Selective protection at 4?ˉ,6?ˉ position was achieved through benzylidenation to provide crude 112 which was converted into epoxide 113 by treatment with sodium methoxide and benzylation. Compound 113 was isolated after filtration on silica gel and crystallization (m.p. 184-5??C). Trans-diaxial opening of the epoxide yielded the 2-azido derivative (66%) which was acetylated to give 114 (99%). The benzylidene was cleaved (92%) and the diol was then converted into 115 by successive tritylation, levulinoylation, detritylation, oxidation, methylation and hydrazinolysis (60% over the 6 steps). Imidate 116 was prepared in the usual way from its hydroxyl precursor and coupled with 115 to give O-linked trisaccharide 117 in 78% yield. Compound 117 was acetolysed (91%), the anomeric acetate was cleaved by benzylamine in ether (100%) and imidate 108 was obtained by reaction with potassium carbonate and trichloroacetonitrile at room temperature (|á, |?- mixture with |á as the predominant isomer, 76%). The preparation of the other building block 109 is described as following. Selective 6-acetylation of 118 by N - acetylimidazole in DCE gave 119 in 60% yield. Treatment of 119 with 120 using DCE/pyridinium perchlorate and followed dechloroacetylation using hydrazinedithiocarbonate afforded the crystalline disaccharide 109.

Drug interactions

Potentially hazardous interactions with other drugs
Increased risk of bleeding in combination with any other drugs that affect coagulation.

Metabolism

Although not fully evaluated, there is no evidence of fondaparinux metabolism and in particular no evidence for the formation of active metabolites. Fondaparinux is excreted to 64-77% by the kidney as unchanged compound.

Fondaparinux sodium Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Fondaparinux sodium Suppliers

Wuxi enqiao Pharmaceutical Technology Co., Ltd
Tel
0510-83591909 18018392058
Fax
0510-83591909
Email
info@enbridgepharm.com
Country
China
ProdList
237
Advantage
58
Hubei Zhongshan Medical Technology Co., Ltd
Tel
027-61907345 13397111514
Fax
3443707954
Email
w13397111514@163.com
Country
China
ProdList
1009
Advantage
58
Biopole Pharmatech Co., Ltd.
Tel
0512-65974739-0 15151475053
Email
mengqi_biopole@163.com
Country
China
ProdList
45
Advantage
58
Chengdu Aupone Pharmaceutical Co.,Ltd.
Tel
18980796919
Email
236656639@qq.com
Country
China
ProdList
30
Advantage
58
Chengdu Aupone Pharmaceutical Co.,Ltd.
Tel
18980796919
Email
236656639@qq.com
Country
China
ProdList
23
Advantage
58
Huadong Microbiology Co., Ltd.
Tel
15858880160
Email
dingya@eastchinapharm.com
Country
China
ProdList
54
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
Beijing HwrkChemical Technology Co., Ltd
Tel
010-89508211 18501085097
Fax
010-89508210
Email
sales.bj@hwrkchemical.com
Country
China
ProdList
8418
Advantage
55
shanghai science Bio-Pharmceutical.co,ltd.
Tel
021-021-57872719 13761402923
Fax
02157872719
Email
245662540@qq.com
Country
China
ProdList
309
Advantage
60
More
Less

View Lastest Price from Fondaparinux sodium manufacturers

Sinoway Industrial co., ltd.
Product
Fondaparinux Sodium 114870-03-0
Price
US $0.00-0.00/Kg/Bag
Min. Order
1Kg/Bag
Purity
99% up, High Density
Supply Ability
20 tons
Release date
2023-09-13
Hebei Weibang Biotechnology Co., Ltd
Product
Fondaparinux sodium 114870-03-0
Price
US $10.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
10 mt
Release date
2024-11-18
Hebei Yanxi Chemical Co., Ltd.
Product
Fondaparinux sodium 114870-03-0
Price
US $30.00-10.00/kg
Min. Order
1kg
Purity
0.99
Supply Ability
20 tons
Release date
2023-11-23

114870-03-0, Fondaparinux sodiumRelated Search:


  • Fondaparin SodiuM
  • Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoaMino)-α-D-glucopyranoside 6-(Hydrogen Sulfate) DecasodiuM Salt
  • Fondaparinux SodiuM Identification
  • Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-α-D-glucopyra
  • Fondaparinux sodium N-4
  • Fondaparinux sodium, >=98%
  • decasodium 6-[[6-[[2-carboxylato-4-hydroxy-6-[[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)-3-oxanyl]oxy]-5-sulfonatooxy-3-oxanyl]oxy]-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatoox
  • decasodium (2R,3S,4S,5R,6R)-3-[(2R,3R,4R,6R)-5-[(2R,3R,4S,5S,6S)-6-carboxylato-5-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-oxan-2-yl]oxy-3-(sulfonatoamino)-4-sulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxy-oxane-2-carboxylate
  • Fondaparinux sodium
  • Arixtra
  • Arixtra (tn)
  • D01844
  • Fondaparinux sodium (jan/usan/inn)
  • Fondaparinux sodiuM(D01844)
  • decasodiuM (2R,3S,4S,5R,6R)-3-{[(2R,3R,4R,5R,6R)-5-{[(2R,3R,4R,5S,6S)-6-carboxylato-5-{[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoaMino)-6-[(sulfonatooxy)Methyl]oxan-2-yl]oxy}-3,4-dihydroxyoxan-2-yl]oxy}-3-(sulfonatoaMino)-4-(sulfonatooxy)-6-[(sulfonatoo
  • a-D-Glucopyranoside, methylO-2-deoxy-6-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(14)-O-b-D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-a-D-glucopyranosyl-(14)-O-2-O-sulfo-a-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-,6-(hydrog
  • Fondaparinux and intermediates
  • Fondaparinux (sodium salt)
  • Natural heparin pentasaccharide Sodium
  • (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-Carboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-((sulfooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-carboxylic acid, decasodium salt
  • Fondaparinux sodium USP/EP/BP
  • (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-Carboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-
  • US-DMF No. : 030767
  • Fondaparinux Sodium (Fondaparinux Sodium)
  • Fondaparinux Sodium Identification(Secondary Standards traceble to USP)
  • Fondaparinux Sodium for Assay (COLD SHIPMENT REQUIRED) (1282707)
  • Fondaparinux Sodium Identification (1282718)
  • Sodium daparinux
  • Fondaparinux Sodiun
  • (2S,3S,4R,5R,6R)-6-(((2R,3R,4R,5R,6R)-6-(((2R,3S,4S,5R,6R)-2-carboxy-4-hydroxy-6-(((2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfooxy)tetrahydro-2H-pyran-3-yl)oxy)-5-(sulfoamino)-4-(sulfooxy)-2-((sulfooxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-3-(((2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-((sulfooxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxytetrahydro-2H-pyran-2-carboxylic acid, sodium salt
  • decasodium 6-[[6-[[2-carboxylato-4-hydroxy-6-[[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)-3-oxanyl]oxy
  • 114870-03-0
  • 14870-03-0
  • C31H43N3O49S810Na
  • C31H43N3Na10O49S8
  • Intermediates & Fine Chemicals
  • Oligosaccharides
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
  • 114870-03-0